In the last trading session, 2.05 million Ensysce Biosciences Inc (NASDAQ:ENSC) shares changed hands as the company’s beta touched 0.71. With the company’s per share price at $0.69 changed hands at -$0.04 or -5.34% during last session, the market valuation stood at $10.82M. ENSC’s last price was a discount, traded about -198.55% off its 52-week high of $2.06. The share price had its 52-week low at $0.14, which suggests the last value was 79.71% up since then. When we look at Ensysce Biosciences Inc’s average trading volume, we note the 10-day average is 86.08 million shares, with the 3-month average coming to 27.13 million.
Analysts gave the Ensysce Biosciences Inc (ENSC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ENSC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Ensysce Biosciences Inc’s EPS for the current quarter is expected to be -0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ensysce Biosciences Inc (NASDAQ:ENSC) trade information
Instantly ENSC was in red as seen at the end of in last trading. With action 19.45%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -34.81%, with the 5-day performance at 19.45% in the green. However, in the 30-day time frame, Ensysce Biosciences Inc (NASDAQ:ENSC) is 288.64% up. Looking at the short shares, we see there were 0.11 million shares sold at short interest cover period of 0.31 days.
Ensysce Biosciences Inc (ENSC) estimates and forecasts
Data shows that the Ensysce Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.12% over the past 6 months, a 69.51% in annual growth rate that is considerably higher than the industry average of 16.80%. Year-over-year growth is forecast to reach -52.90% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 250k. 2 analysts are of the opinion that Ensysce Biosciences Inc’s revenue for the current quarter will be 240k. The estimates for the next quarter sales put growth at -53.40%.
The 2024 estimates are for Ensysce Biosciences Inc earnings to increase by 76.33%.
ENSC Dividends
Ensysce Biosciences Inc is expected to release its next quarterly earnings report in December.
Ensysce Biosciences Inc (NASDAQ:ENSC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.17% of Ensysce Biosciences Inc shares while 21.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 22.22%. There are 21.96% institutions holding the Ensysce Biosciences Inc stock share, with PLANTE MORAN FINANCIAL ADVISORS, LLC the top institutional holder. As of 2024-06-30, the company held 0.0004% of the shares, roughly 20.0 ENSC shares worth $10.0.
